



T2 PROTECT AD

Troriluzole (BHV-4157) Trial (T2) for Alzheimer's Disease

The Troriluzole (BHV-4157)
Trial in Alzheimer's Disease



The T2 Protect AD Study is a national multi-site clinical trial testing an investigational drug for people with mild to moderate Alzheimer's disease (AD). The trial is designed to determine if the study drug can protect against, or slow down, memory and thinking problems that increase as Alzheimer's disease progresses.

T2 Protect AD Basic Eligibility Criteria

- Women and men aged 50-85
- Diagnosed with mild to moderate Alzheimer's disease
- If taken, stable Alzheimer's medication(s):
 - Donepezil/Aricept® or rivastigmine/Exelon® or galantamine/Razadyne®
 - With or without memantine/Namenda®
- Living in the community (not in a residential nursing home)
- Participants must have a study partner who knows the participant well and can come to study visits.
- Willing to participate in the T2 Study for 48 weeks

What happens during the T2 Protect Study?

Participation in the study will take 48 weeks. A potential participant will first go through a screening process to see if they are eligible to take part in the clinical trial. Participants will take Troriluzole or placebo (an inactive substance).

Screening includes:

- Memory and thinking tests
- EKGs (a look at your heart rhythms)
- MRI scans (a picture of your brain that shows changes related to Alzheimer's disease)

For more information or to volunteer, please contact:

Elaine Peskind, MD

VA Puget Sound Health Care System

1660 S. Columbian Way
Seattle, WA 98108

206-764-2069

www.T2Protect.org